|Mr. Robert W. Azelby||Pres, CEO & Director||791.63k||N/A||1968|
|Mr. Carlos Campoy||Chief Financial Officer||398.2k||N/A||1965|
|Ms. Erin M. Lavelle||Chief Operating Officer||955.12k||N/A||1978|
|Mr. James B. Bucher||Exec. VP, Gen. Counsel & Corp. Sec.||594.64k||N/A||1966|
|Mr. Randal A. Hassler||Exec. Sr. VP of Pharmaceutical Operations||N/A||N/A||1957|
Alder BioPharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine in the United States, Australia, and Ireland. The company's lead product candidate is eptinezumab, a monoclonal antibody (mAb) inhibiting calcitonin gene-related peptide, which is in the late-stage clinical development for the prevention of migraine. It also develops ALD1910, a preclinical mAb that inhibits pituitary adenylate cyclase-activating polypeptide-38 for migraine prevention; and Clazakizumab, a mAb inhibiting the pro-inflammatory cytokine interleukin-6 that has completed two Phase 2b clinical trials. The company has strategic collaboration with CSL Limited for the development of clazakizumab as a therapeutic option for solid organ transplant rejection. Alder BioPharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Bothell, Washington.
Alder BioPharmaceuticals, Inc.’s ISS Governance QualityScore as of April 1, 2019 is 9. The pillar scores are Audit: 5; Board: 9; Shareholder Rights: 8; Compensation: 8.